Servier has been doing cancer deals for more than 10 years, but dramatically picked up the pace in 2011. The pharma is seeking ex-U.S. and ex-Japan rights to novel compounds in Phase II or earlier focused on apoptosis, kinase inhibition and/or immunomodulation. Most recent deals at top. Source: BCIQ: BioCentury Online Intelligence

Partner

Description

Financial details

Target

Status at time of deal

Date

Ethical Oncology Science S.p.A.

Co-develop E-3810 for cancer; Servier has exclusive rights outside the U.S., Japan and China

€45M ($57.9M) up front; undisclosed milestones and royalties

Fibroblast growth factor (FGF) receptor 1 (FGFR1; CD331) and vascular endothelial growth factor (VEGF)

Ph I/II [solid tumors]; start Ph II in 1Q13 [breast cancer, non-small lung cancer (NSCLC)]

Oct-12